ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : gene function
Scheme : NHMRC Strategic Awards
Clear All
Filter by Field of Research
Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies) (1)
Genetics Not Elsewhere Classified (1)
Genome Structure and Regulation (1)
Geriatrics And Gerontology (1)
Medical and Health Sciences (1)
Medical biochemistry - inorganic elements and compounds (1)
Neurosciences not elsewhere classified (1)
Opthalmology And Vision Science (1)
Primary Health Care (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (10)
Filter by Status
Closed (10)
Filter by Scheme
NHMRC Strategic Awards (10)
Filter by Country
Australia (1)
Filter by Australian State/Territory
VIC (1)
  • Researchers (0)
  • Funded Activities (10)
  • Organisations (21)
  • Funded Activity

    Targeting CD4-positive Cells For Anti-HIV Gene Therapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $356,646.00
    Summary
    Treatment of HIV early following infection is thought to be important for maximising the quality of life of patients. Conventional therapy has had some success in early intervention but resistance invariably develops. This application proposes to develop a gene therapy approach to elimiate HIV infected cells by introducing a suicide gene into those cells that harbor the virus. The advantage of this approach is the limited toxicity that is associated with gene therapies as well as the ability to .... Treatment of HIV early following infection is thought to be important for maximising the quality of life of patients. Conventional therapy has had some success in early intervention but resistance invariably develops. This application proposes to develop a gene therapy approach to elimiate HIV infected cells by introducing a suicide gene into those cells that harbor the virus. The advantage of this approach is the limited toxicity that is associated with gene therapies as well as the ability to target specific cell-types. It is proposed to genetically modify a strain of adenovirus to introduce a gene that will kill cells that it infects that also contain HIV. This is a novel approach and potentially may be an important treatment in the future. Anti-HIV gene therapy may also be useful in addition to the more conventional treatments.
    Read more Read less
    More information
    Funded Activity

    DISCOVERY OF GENES PREDISPOSING TO JUVENILE DIABETES AND ITS COMPLICATIONS

    Funder
    National Health and Medical Research Council
    Funding Amount
    $940,000.00
    More information
    Funded Activity

    The Assessment & Pervalence Of Dementia In Aboriginal & Torres Strait Islander People In The Kimberley Region

    Funder
    National Health and Medical Research Council
    Funding Amount
    $200,000.00
    More information
    Funded Activity

    THE DETECTION AND MANAGEMENT OF DEMENTIA IN GENERAL PRACTICE.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $499,977.00
    Summary
    This research aims to examine a new method and practice guidelines for detection of early dementia. General practitioners will be screened on their ability to diagnose and manage dementia and to distinguish it from other diseases. Patient outcomes - including quality of life, depression, and satisfaction with care and referral indicators - will be examined.
    More information
    Funded Activity

    Cognitive Outcome And Therapeutic Interventions For Coronary Artery Disease.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $392,104.00
    Summary
    Dementia is recognized as an increasingly important factor affecting quality of life as people age. Deaths from heart disease are declining, in part due to improved surgical techniques and to the use of less invasive methods to keep arteries open such as coronary stenting. It is now well known that 20 to 60% of patients experience some degree of impairment in thinking ability (cognitive impairment) after cardiac surgery, that this will persist in some of these individuals for years and may incre .... Dementia is recognized as an increasingly important factor affecting quality of life as people age. Deaths from heart disease are declining, in part due to improved surgical techniques and to the use of less invasive methods to keep arteries open such as coronary stenting. It is now well known that 20 to 60% of patients experience some degree of impairment in thinking ability (cognitive impairment) after cardiac surgery, that this will persist in some of these individuals for years and may increase the risk of long-term problems. Cognitive impairment affects people in many ways. While it is not yet known whether the occurrence of cognitive impairment predisposes to dementia, it is thought that Mild Cognitive Impairment (MCI) may do so. We propose to explore the link between MCI and Post Procedural Cognitive Deficit (PPCD) in patients with coronary disease from before the first point of objective diagnosis, i.e. prior to the coronary angiogram, and over a 12-month period, through and subsequent to further treatment interventions such as stenting or cardiac surgery. Our Pilot data suggest that PPCD does indeed occur after angiography, and we propose to identify how long this lasts, whether MCI predisposes to it and whether it is better to wait until it resolves before further interventions are undertaken. In this way we hope to identify the safest treatment strategy for patients with coronary disease that will minimize the occurrence of Cognitive Deficit and possibly longer-term cognitive changes after investigation and treatment for their symptoms.
    Read more Read less
    More information
    Funded Activity

    Use Of The Norfolk Island Genetic Isolate For Disease Gene Mapping

    Funder
    National Health and Medical Research Council
    Funding Amount
    $978,500.00
    Summary
    This gene mapping study will use a unique founder effect population to investigate two major public health disorders. We aim to identify genes that play a role in migraine and in cardiovascular disease, using a population from Norfolk Island. The Norfolk Island community is a population of ~1200 permanent residents, the majority of whom are direct descendents of 18th century English Bounty mutineers and Polynesian women. We will undertake a full genome scan to identify migraine gene loci and QTL .... This gene mapping study will use a unique founder effect population to investigate two major public health disorders. We aim to identify genes that play a role in migraine and in cardiovascular disease, using a population from Norfolk Island. The Norfolk Island community is a population of ~1200 permanent residents, the majority of whom are direct descendents of 18th century English Bounty mutineers and Polynesian women. We will undertake a full genome scan to identify migraine gene loci and QTL that influence cardiovascular disease using samples from this population isolate.
    Read more Read less
    More information
    Funded Activity

    Gene Based Treatment Strategies For Diabetic Retinopathy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $2,630,000.00
    Summary
    Diabetic retinopathy is the leading cause of blindness in the working population of developed countries and it is an increasing problem in the developing world. Present therapy involves extensive laser destruction of the light-detecting part of he retina. In addition, it is not only effective when administered at an appropriate stage in the disease process. Consequently, there is an urgent need for the development of better, prophylactic, easily administrable and cheaper therapies. This project .... Diabetic retinopathy is the leading cause of blindness in the working population of developed countries and it is an increasing problem in the developing world. Present therapy involves extensive laser destruction of the light-detecting part of he retina. In addition, it is not only effective when administered at an appropriate stage in the disease process. Consequently, there is an urgent need for the development of better, prophylactic, easily administrable and cheaper therapies. This project aims to develop a potentially permanent solution to alleviate diabetes-related blindness in the world. The project combines several very recent scientific advances into one strategy to combat diabetic retinopathy at a molecular level. Vision is our most important sensory organ that cannot be replaced. Thus, human trials can only be conducted following extensive animal safety and efficacy trials. To date the development of new therapies has been seriously hampered by the lack of appropriate, easy to reproduce animal models for different stages of diabetic retinopathy. In addition, it aims to identify new therapeutic agents from molecules that are naturally produced by the retina while fighting the disease. Finally, tested and evaluated in the animal models. The most successful therapeutic candidates will then be further developed for human trials.If successful, our approach will potentially have a major impact on the treatment of diabetic retinopathy and possibly on all diabetic vascular diseases. A single injection might only be necessary to prevent the development of diabetic retinopathy, which would represent a significant weapon in the management of patients. In addition, successful application of secretion gene therapy in the eye might open up the possibility to introduce the same concept for the treatment of larger organs undergoing microvascular changes as a result of diabetes.
    Read more Read less
    More information
    Funded Activity

    Roles Of Enzymes Of The Dipeptidyl Peptidase Gene Family In Human Liver

    Funder
    National Health and Medical Research Council
    Funding Amount
    $79,750.00
    Summary
    Chronic liver diseases, particularly those caused by autoimmune disease, alcohol and Hepatitis B and C virus infection, are major causes of morbidity and mortality in our community. They are characterised by progressive scarring of the liver which finally leads to liver failure and the need in many cases for organ transplantation. Each year 15,000 Australians become infected, probably for life, with hepatitis C virus. Unless more effective treatments are developed approximately 20% of these infe .... Chronic liver diseases, particularly those caused by autoimmune disease, alcohol and Hepatitis B and C virus infection, are major causes of morbidity and mortality in our community. They are characterised by progressive scarring of the liver which finally leads to liver failure and the need in many cases for organ transplantation. Each year 15,000 Australians become infected, probably for life, with hepatitis C virus. Unless more effective treatments are developed approximately 20% of these infections will progress to liver failure or liver cancer within 30 years. Diabetes afflicts 150 million people, and 90% have Type 2 diabetes. We request funding of our research on a family of enzymes highly prospective as targets for novel therapies for these diseases. We are internationally recognised experts on this enzyme family and on liver disease. The prototype member of this enzyme family, dipeptidyl peptidase (DP) IV, is being targeted by novel drugs that are in phase III clinical trials for Type 2 diabetes. Family member fibroblast activation protein (FAP) is targeted by novel anti-cancer drugs We were first to clone and lodge patent applications for two new enzymes of this family, DP8 and DP9. Our research proposal would lead to determination of whether FAP, DP8 and-or DP9 are valuable targets for novel liver disease therapeutics and facilitate generating the development of such therapeutics by a more thorough understanding of the activities and roles of these enzymes Completion of this project will greatly increase our understanding of these enzymes and their roles in chronic liver injury. This work can potentially lead to the development of specific inhibitors of enzyme function designed to relieve liver damage.
    Read more Read less
    More information
    Funded Activity

    Mapping Genes For Typical Migraine Using Twin Families.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $439,124.00
    Summary
    Current evidence suggests multiple genes may underlie susceptibility to the more common forms of migraine. The project will look to see if the these genes provide clues to the further elucidation of the complex molecular pathways of migraine and will help in the development of diagnostic tests and evidence-based treatment strategies.
    More information
    Funded Activity

    Translational Control During HIV-1 Replication

    Funder
    National Health and Medical Research Council
    Funding Amount
    $398,994.00
    Summary
    HIV infection of CD4+ lymphocytes leads to a high rate of reproduction of new virus. However, in the brain, HIV infection of the astrocytes does not yield high levels of new virus. HIV is genetically active in these astrocytes, producing high levels of the messenger molecules, the so-called mRNA, that code for the proteins required for a new virus particle. We have determined that these HIV mRNAs are specifically prevented from translating into protein. The mechanisms controlling protein transla .... HIV infection of CD4+ lymphocytes leads to a high rate of reproduction of new virus. However, in the brain, HIV infection of the astrocytes does not yield high levels of new virus. HIV is genetically active in these astrocytes, producing high levels of the messenger molecules, the so-called mRNA, that code for the proteins required for a new virus particle. We have determined that these HIV mRNAs are specifically prevented from translating into protein. The mechanisms controlling protein translation from RNA are relatively poorly understood compared with the other control points of cellular gene expression, such as the synthesis of mRNA. This project examines how astrocytes rapidly detect the presence of HIV mRNA and alter their translation machinery to halt the expression of HIV protein. This host defence mechanism involves two key components; the cellular component that identifies and responds to the viral mRNA, and the structural features of the HIV mRNA that enable the cell to detect its viral origin. We will study how translation of HIV proteins requires both HIV and cellular factors. We will determine the impact of both viral RNA elements and viral RNA binding proteins on the translation of viral and cellular proteins. The contribution of the type-1 interferons that are produced in response to viral infection will be studied for their role in augmenting the inhibition of HIV protein translation. Since HIV infected astrocytes significantly contribute to the onset of AIDS dementia, we will sees a strategy to lock HIV into a dormant state in the brain and thereby prevent the neurodegenerative disease associated with HIV. We will use the anti-viral mechanism blocking HIV protein translation in astrocytes to protect other cell populations, such as the CD4+ lymphocytes, from HIV infection. These studies will also give insights into the general mechanisms for translational control of gene expression in human cells.
    Read more Read less
    More information

    Showing 1-10 of 10 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback